With a single dose of the new opioid Ieraplastin you could potentially help people with ALS, according to a study published in the American Journal of Cardiology.
Ierapherepheroin is the first opioid to be approved by the Food and Drug Administration (FDA) for the treatment of ALS, which is a degenerative disease of the central nervous system.
Ieripropylin is a type of opioid that is used to treat other chronic pain conditions.
“Our study found that patients with primary progressive ALS who received an intravenous infusion of Ierapeptheptol-8 and Ierapo-9 showed significantly better neurological outcome compared to those who received either placebo or an intra-abdominal infusion of placebo,” Dr. Raghuram Kulkarni, co-author of the study, said in a statement.
“This is very encouraging news, as we have seen many other studies showing that opioid therapy may be effective in the treatment and even prevention of ALS.
We believe that we can now demonstrate that intravenous injection of these compounds, particularly when combined with other opioids, may offer a potential new approach to this disease.”
The study was done in mice that were genetically engineered to be resistant to Ierpherepher-8, and used two different strains of mice.
One strain of mice received the intravenous dose of IERapherempher-9, while the other one received placebo.
The researchers found that when given Ierppherephere-9 combined with the placebo, mice with primary ALS were less likely to develop signs of progression to ALS than mice that received placebo alone.
They also found that Ierapiapherepthepsin, an opioid-like substance, significantly inhibited the development of symptoms of ALS in these mice.
The study found similar results when they tested the mice in a different group of mice that had not been genetically engineered with the resistance to IERPherephepsine, but were genetically resistant to the two other types of opioids.
The team says that the findings could have implications for the development and clinical application of a drug for treating ALS, and could help explain why some people with the disease have had difficulty recovering from other treatments for ALS.
This is a very important development, said Dr. Daniel Gavrilovich, senior author of the paper, in a press release.
“The results are very promising, as these mice are not only genetically engineered and have been engineered to develop resistance to the opioid receptor antagonists IerPhereppherepsin and IERipropherpsin,” he said.
“But also the researchers have shown that the combination of the two compounds is able to significantly attenuate neurodegenerative disease-related changes, which we hope to be able to translate into a drug that could be more effective for treating these patients.”
While these results could provide hope for patients who have had ALS, it’s also important to note that these mice were also given a different type of drug known as arginine oxidase inhibitor, or ALXI-6, which has also been shown to be effective against the development or progression of ALS-like symptoms in mice.
Dr. Kulkhan said that ALXIs were developed in the early 1980s, and are currently the only effective treatment for patients with the progressive neurodegender disease.
However, studies have shown they are not as effective as the more common NMDA antagonists.
“This is important to realize that ALOXIs, because of their high potency, are not well tolerated by most people,” Dr Kulkavir said.
The authors of the ALXi-6 study are also the authors of a paper published in 2016 that showed the efficacy of a new anti-inflammatory drug, amantadine, in the clinical trial of patients with amyotrophic lateral sclerosis (ALS).
This study was published in PLOS One.
Follow Jamie on Twitter